Report Detail
Global Transdermal Drug Delivery System Market Size, Status and Forecast 2019-2025
- RnM2937032 |
- 13 February, 2019 |
- Global |
- 103 Pages |
- QYResearch |
- Other
Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.
The classification of Transdermal Drug Delivery System includes Fentanyl, Nitroglycerin, Estradiol, Nicotine and Other, and the revenue proportion of Fentanyl in 2016 is about 31.1%. Transdermal Drug Delivery System can be used for OTC, Rx. The most proportion of Transdermal Drug Delivery System is OTC, and the sales proportion is about 83.3% in 2016.
North America is the largest sales place, with a revenue market share nearly 41% in 2016. Following North America, Europe is the second largest sales place with the revenue market share of 28%. China and Japan are also important sales regions for Transdermal Drug Delivery System.
The unprecedented global shift in the adoption of unhealthy lifestyles is to be responsible for the high prevalence of chronic diseases, such as cancer and diabetes, which is expected to drive the clinical urgency to incorporate transdermal drug delivery systems in the future treatments. Moreover, the rising geriatric population base, which is highly susceptible to developing the aforementioned chronic diseases are expected to propel the demand for highly efficacious pharmacological drugs.
Market competition is intense. Hisamitsu, Mylan, Johnson & Johnson, Actavis, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
In 2018, the global Transdermal Drug Delivery System market size was 8950 million US$ and it is expected to reach 24300 million US$ by the end of 2025, with a CAGR of 13.3% during 2019-2025.
This report focuses on the global Transdermal Drug Delivery System status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Transdermal Drug Delivery System development in United States, Europe and China.
The key players covered in this study
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum Company
Laboratoires Genevrier
Market segment by Type, the product can be split into
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other
Market segment by Application, split into
OTC
Rx
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Transdermal Drug Delivery System status, future forecast, growth opportunity, key market and key players.
To present the Transdermal Drug Delivery System development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Transdermal Drug Delivery System are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Transdermal Drug Delivery System Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Fentanyl
- 1.4.3 Nitroglycerin
- 1.4.4 Estradiol
- 1.4.5 Nicotine
- 1.4.6 Other
- 1.5 Market by Application
- 1.5.1 Global Transdermal Drug Delivery System Market Share by Application (2014-2025)
- 1.5.2 OTC
- 1.5.3 Rx
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Transdermal Drug Delivery System Market Size
- 2.2 Transdermal Drug Delivery System Growth Trends by Regions
- 2.2.1 Transdermal Drug Delivery System Market Size by Regions (2014-2025)
- 2.2.2 Transdermal Drug Delivery System Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Opportunities
3 Market Share by Key Players
- 3.1 Transdermal Drug Delivery System Market Size by Manufacturers
- 3.1.1 Global Transdermal Drug Delivery System Revenue by Manufacturers (2014-2019)
- 3.1.2 Global Transdermal Drug Delivery System Revenue Market Share by Manufacturers (2014-2019)
- 3.1.3 Global Transdermal Drug Delivery System Market Concentration Ratio (CR5 and HHI)
- 3.2 Transdermal Drug Delivery System Key Players Head office and Area Served
- 3.3 Key Players Transdermal Drug Delivery System Product/Solution/Service
- 3.4 Date of Enter into Transdermal Drug Delivery System Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Transdermal Drug Delivery System Market Size by Type (2014-2019)
- 4.2 Global Transdermal Drug Delivery System Market Size by Application (2014-2019)
5 United States
- 5.1 United States Transdermal Drug Delivery System Market Size (2014-2019)
- 5.2 Transdermal Drug Delivery System Key Players in United States
- 5.3 United States Transdermal Drug Delivery System Market Size by Type
- 5.4 United States Transdermal Drug Delivery System Market Size by Application
6 Europe
- 6.1 Europe Transdermal Drug Delivery System Market Size (2014-2019)
- 6.2 Transdermal Drug Delivery System Key Players in Europe
- 6.3 Europe Transdermal Drug Delivery System Market Size by Type
- 6.4 Europe Transdermal Drug Delivery System Market Size by Application
7 China
- 7.1 China Transdermal Drug Delivery System Market Size (2014-2019)
- 7.2 Transdermal Drug Delivery System Key Players in China
- 7.3 China Transdermal Drug Delivery System Market Size by Type
- 7.4 China Transdermal Drug Delivery System Market Size by Application
8 Japan
- 8.1 Japan Transdermal Drug Delivery System Market Size (2014-2019)
- 8.2 Transdermal Drug Delivery System Key Players in Japan
- 8.3 Japan Transdermal Drug Delivery System Market Size by Type
- 8.4 Japan Transdermal Drug Delivery System Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Transdermal Drug Delivery System Market Size (2014-2019)
- 9.2 Transdermal Drug Delivery System Key Players in Southeast Asia
- 9.3 Southeast Asia Transdermal Drug Delivery System Market Size by Type
- 9.4 Southeast Asia Transdermal Drug Delivery System Market Size by Application
10 India
- 10.1 India Transdermal Drug Delivery System Market Size (2014-2019)
- 10.2 Transdermal Drug Delivery System Key Players in India
- 10.3 India Transdermal Drug Delivery System Market Size by Type
- 10.4 India Transdermal Drug Delivery System Market Size by Application
11 Central & South America
- 11.1 Central & South America Transdermal Drug Delivery System Market Size (2014-2019)
- 11.2 Transdermal Drug Delivery System Key Players in Central & South America
- 11.3 Central & South America Transdermal Drug Delivery System Market Size by Type
- 11.4 Central & South America Transdermal Drug Delivery System Market Size by Application
12 International Players Profiles
- 12.1 Hisamitsu
- 12.1.1 Hisamitsu Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Transdermal Drug Delivery System Introduction
- 12.1.4 Hisamitsu Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.1.5 Hisamitsu Recent Development
- 12.2 Mylan
- 12.2.1 Mylan Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Transdermal Drug Delivery System Introduction
- 12.2.4 Mylan Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.2.5 Mylan Recent Development
- 12.3 GSK
- 12.3.1 GSK Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Transdermal Drug Delivery System Introduction
- 12.3.4 GSK Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.3.5 GSK Recent Development
- 12.4 Novartis
- 12.4.1 Novartis Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Transdermal Drug Delivery System Introduction
- 12.4.4 Novartis Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.4.5 Novartis Recent Development
- 12.5 Teve (Actavis)
- 12.5.1 Teve (Actavis) Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Transdermal Drug Delivery System Introduction
- 12.5.4 Teve (Actavis) Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.5.5 Teve (Actavis) Recent Development
- 12.6 Johnson & Johnson
- 12.6.1 Johnson & Johnson Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Transdermal Drug Delivery System Introduction
- 12.6.4 Johnson & Johnson Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.6.5 Johnson & Johnson Recent Development
- 12.7 Lohmann
- 12.7.1 Lohmann Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Transdermal Drug Delivery System Introduction
- 12.7.4 Lohmann Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.7.5 Lohmann Recent Development
- 12.8 Teikoku Seiyaku
- 12.8.1 Teikoku Seiyaku Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Transdermal Drug Delivery System Introduction
- 12.8.4 Teikoku Seiyaku Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.8.5 Teikoku Seiyaku Recent Development
- 12.9 Bayer
- 12.9.1 Bayer Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Transdermal Drug Delivery System Introduction
- 12.9.4 Bayer Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.9.5 Bayer Recent Development
- 12.10 Lingrui
- 12.10.1 Lingrui Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Transdermal Drug Delivery System Introduction
- 12.10.4 Lingrui Revenue in Transdermal Drug Delivery System Business (2014-2019)
- 12.10.5 Lingrui Recent Development
- 12.11 Sanofi
- 12.12 Qizheng
- 12.13 Endo
- 12.14 Huarun 999
- 12.15 Haw Par
- 12.16 Nichiban
- 12.17 Mentholatum Company
- 12.18 Laboratoires Genevrier
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Transdermal Drug Delivery System . Industry analysis & Market Report on Transdermal Drug Delivery System is a syndicated market report, published as Global Transdermal Drug Delivery System Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Transdermal Drug Delivery System market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
